BCPCMEDIUM SIGNALFINANCIAL10-K

BCPC delivered strong financial performance with 13.6% revenue growth to $799M and 20.5% net income growth to $154.8M, while strengthening its balance sheet through debt reduction and cash generation.

The company demonstrated robust operational execution with operating cash flow increasing 19% to $216.6M while simultaneously reducing total debt by 11.8% to $262.5M. The strong financial performance, combined with increased capital expenditures of 35.8% to $49.1M, suggests the company is investing in growth while maintaining disciplined capital allocation.

Comparing 2026-02-20 vs 2025-02-21View on EDGAR →
FINANCIAL ANALYSIS

BCPC showed across-the-board financial strength with revenue growing 13.6% to $799M driving net income up 20.5% to $154.8M, demonstrating improving operating leverage. The balance sheet strengthened significantly with cash increasing 50.6% to $74.6M while total debt decreased 11.8% to $262.5M, funded by strong operating cash flow of $216.6M. The 35.8% increase in capital expenditures to $49.1M indicates the company is investing in future growth while maintaining excellent liquidity and reducing financial risk.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+50.6%
$49.5M→$74.6M

Cash position surged 50.6% — strong cash generation or capital raise providing significant financial cushion.

Capital Expenditure
Cash Flow
+35.8%
$36.1M→$49.1M

Capital expenditure jumped 35.8% — major investment cycle underway; assess returns on deployment.

Net Income
P&L
+20.5%
$128.5M→$154.8M

Net income grew 20.5% — bottom-line growth signals improving overall business health.

Accounts Receivable
Balance Sheet
+20%
$119.7M→$143.6M

Receivables grew 20% — monitor days sales outstanding for collection efficiency.

Operating Cash Flow
Cash Flow
+19%
$182.0M→$216.6M

Operating cash flow grew 19% — strong conversion of earnings to cash, healthy business fundamentals.

Current Assets
Balance Sheet
+16.5%
$313.8M→$365.6M

Current assets grew 16.5% — improving short-term liquidity or inventory/receivables build.

Operating Income
P&L
+14.4%
$182.9M→$209.3M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Revenue
P&L
+13.6%
$703.6M→$799.0M

Revenue growing 13.6% — solid top-line momentum, watch margins for quality of growth.

Current Liabilities
Balance Sheet
+11.9%
$157.7M→$176.4M

Current liabilities rose 11.9% — increased short-term obligations, watch current ratio.

Total Debt
Balance Sheet
-11.8%
$297.5M→$262.5M

Debt reduced 11.8% — deleveraging strengthens balance sheet and reduces financial risk.

LANGUAGE CHANGES
NEW — 2026-02-20
PRIOR — 2025-02-21
ADDED
Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 7A.
We develop, manufacture, distribute and market specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, plant nutrition, sterilization, fumigation, and industrial markets.
Sales of value-added encapsulated products are highly dependent on overall industry economics as well as the Company's ability to leverage the results of university and field research on the animal health and production benefits of our products.
Raw Materials The raw materials utilized by us in the manufacture of our products are sourced from suppliers both domestically and internationally.
We experienced inflationary patterns in 2025, including from certain tariffs, in several categories that we source.
Backlog At December 31, 2025, we had a total backlog of $53,365 (comprised of $39,587 for the HNH segment; $11,489 for the ANH segment; $1,933 for the SP segment, and $356 for other), as compared to a total backlog of $50,415 at December 31, 2024 (comprised of $39,959 for the HNH segment; $9,035 for the ANH segment; $1,284 for the SP segment and $137 for other).
In late June 2025, the European Commission announced that it would impose provisional duties between 95.4% and 120.8% on imports into the European Union of choline chloride originating in the People s Republic of China, effective July 1, 2025.
The investigation was initiated by the European Commission in late October 2024, following a complaint lodged by Balchem Italia Srl and another complainant.
On December 19, 2025, the European Commission published their final decision to set definitive duties between 90.0% and 115.9%.
Further, the European Commission set rules to make it clear that the country of origin of choline chloride, regardless of form, will be the country where the chemical reaction between trimethylamine hydrochloride and ethylene oxide takes place.
REMOVED
Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 7A.
We develop, manufacture, distribute and market specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets.
Specialty Products The Company re-packages and distributes a number of performance gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia.
Significant Acquisitions On August 30, 2022, the Company's wholly-owned subsidiary Albion Laboratories, Inc.
("Albion") entered into a Stock Purchase Agreement, and closed on such transaction with Cardinal Associates Inc.
("Cardinal"), a corporation organized under the laws of the State of Washington, pursuant to which Albion acquired Cardinal and its Bergstrom Nutrition business (collectively, "Bergstrom").
Bergstrom is a leading science-based manufacturer of MSM, based in Vancouver, Washington.
Details related to the Bergstrom acquisition are disclosed in Note 2, Significant Acquisitions .
The addition of OptiMSM , Bergstrom Nutrition's MSM brand, to the Company's portfolio within the Human Nutrition and Health and Animal Nutrition and Health segments provides a synergistic scientific advantage in Balchem's key strategic therapeutic focus areas such as longevity and performance and is a strong fit with Balchem's specialty, science-backed mineral products.
On June 21, 2022, the Company and its wholly-owned subsidiary, Balchem B.V., completed the acquisition of Kechu BidCo AS and its subsidiary companies, including Kappa Bioscience AS, a leading science-based manufacturer of specialty vitamin K2 for the human nutrition industry, headquartered in Oslo, Norway (all acquired companies collectively referred to as Kappa ).
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →